{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T05:00:08Z","timestamp":1792558808380,"version":"4.5.0"},"reference-count":135,"publisher":"Elsevier","isbn-type":[{"value":"9780443238321","type":"print"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.pmbts.2025.01.005","type":"book-chapter","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:08:06Z","timestamp":1743638886000},"page":"135-169","source":"Crossref","is-referenced-by-count":1,"title":["Guardians at the gate: Unraveling Type I interferon\u2019s role and challenges posed by anti-interferon antibodies in COVID-19"],"prefix":"10.1016","author":[{"given":"Alaa A.A.","family":"Aljabali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Obeid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Gammoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"El-Tanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murtaza M.","family":"Tambuwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/bs.pmbts.2025.01.005_bib1","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3389\/fimmu.2019.00778","article-title":"Sources of type I interferons in infectious immunity: plasmacytoid dendritic cells not always in the driver\u2019s seat","volume":"10","author":"Ali","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/bs.pmbts.2025.01.005_bib2","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/B978-0-12-809633-8.21290-9","article-title":"Antiviral innate immunity: introduction","author":"Weber","year":"2021","journal-title":"Encycl Virol"},{"issue":"2","key":"10.1016\/bs.pmbts.2025.01.005_bib3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nri3787","article-title":"Type I interferons in infectious disease","volume":"15","author":"McNab","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/bs.pmbts.2025.01.005_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.608645","article-title":"Importance of type I and III interferons at respiratory and intestinal barrier surfaces","volume":"11","author":"Stanifer","year":"2020","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/bs.pmbts.2025.01.005_bib5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2174\/2211738508999200817163335","article-title":"COVID-19: underpinning research for detection, therapeutics, and vaccines development","volume":"8","author":"Aljabali","year":"2020","journal-title":"Pharm Nanotechnol"},{"issue":"13","key":"10.1016\/bs.pmbts.2025.01.005_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22137017","article-title":"Innate immune response to SARS-CoV-2 infection: from cells to soluble mediators","volume":"22","author":"Ricci","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/bs.pmbts.2025.01.005_bib7","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.cell.2021.02.029","article-title":"COVID-19 and the human innate immune system","volume":"184","author":"Schultze","year":"2021","journal-title":"Cell"},{"issue":"1","key":"10.1016\/bs.pmbts.2025.01.005_bib8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12985-024-02287-0","article-title":"Unraveling the dynamic mechanisms of natural killer cells in viral infections: insights and implications","volume":"21","author":"Letafati","year":"2024","journal-title":"Virol J"},{"issue":"11","key":"10.1016\/bs.pmbts.2025.01.005_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102941","article-title":"Autoimmunity roots of the thrombotic events after COVID-19 vaccination","volume":"20","author":"Elrashdy","year":"2021","journal-title":"Autoimmunity Rev"},{"key":"10.1016\/bs.pmbts.2025.01.005_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2022.153848","article-title":"The role of antigen-presenting cells in the pathogenesis of COVID-19","volume":"233","author":"Farzi","year":"2022","journal-title":"Pathol Res Pract"},{"issue":"10","key":"10.1016\/bs.pmbts.2025.01.005_bib11","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.3390\/v13101927","article-title":"Potential molecular mechanisms of rare anti-tumor immune response by SARS-CoV-2 in isolated cases of lymphomas","volume":"13","author":"Barh","year":"2021","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/bs.pmbts.2025.01.005_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms10030501","article-title":"Innate immune response in SARS-CoV-2 infection","volume":"10","author":"Schiuma","year":"2022","journal-title":"Microorganisms"},{"issue":"1","key":"10.1016\/bs.pmbts.2025.01.005_bib13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12941-021-00438-7","article-title":"COVID-19: breaking down a global health crisis","volume":"20","author":"Mallah","year":"2021","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"6","key":"10.1016\/bs.pmbts.2025.01.005_bib14","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41579-023-00878-2","article-title":"The evolution of SARS-CoV-2","volume":"21","author":"Markov","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/bs.pmbts.2025.01.005_bib15","article-title":"Factors responsible for the emergence of novel viruses: an emphasis on SARS-CoV-2","volume":"27","author":"Mohapatra","year":"2022","journal-title":"Curr Opin Env Sci Health"},{"issue":"11","key":"10.1016\/bs.pmbts.2025.01.005_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/v12111203","article-title":"Viewpoint: origin of SARS-CoV-2","volume":"12","author":"Lundstrom","year":"2020","journal-title":"Viruses"},{"issue":"7889","key":"10.1016\/bs.pmbts.2025.01.005_bib17","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/s41586-021-04188-6","article-title":"The emergence, genomic diversity and global spread of SARS-CoV-2","volume":"600","author":"Li","year":"2021","journal-title":"Nature"},{"issue":"3","key":"10.1016\/bs.pmbts.2025.01.005_bib18","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"10.1016\/bs.pmbts.2025.01.005_bib19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12985-023-01989-1","article-title":"The detectable anti-interferon-\u03b3 autoantibodies in COVID-19 patients may be associated with disease severity","volume":"20","author":"Chen","year":"2023","journal-title":"Virol J"},{"issue":"4","key":"10.1016\/bs.pmbts.2025.01.005_bib20","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1016\/S2665-9913(21)00034-5","article-title":"Type I interferon, anti-interferon antibodies, and COVID-19","volume":"3","author":"Calabrese","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"10.1016\/bs.pmbts.2025.01.005_bib21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41423-023-01104-y","article-title":"SARS-CoV-2 and innate immunity: the good, the bad, and the \u201cgoldilocks\u201d","volume":"21","author":"Sievers","year":"2024","journal-title":"Cell Mol Immunol"},{"issue":"7","key":"10.1016\/bs.pmbts.2025.01.005_bib22","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.it.2020.05.005","article-title":"A future outlook on molecular mechanisms of immunity","volume":"41","author":"Weinmann","year":"2020","journal-title":"Trends Immunol"},{"issue":"7","key":"10.1016\/bs.pmbts.2025.01.005_bib23","article-title":"Next-generation sequencing technology: current trends and advancements","volume":"12","author":"Satam","year":"2023","journal-title":"Biol (Basel)"},{"key":"10.1016\/bs.pmbts.2025.01.005_bib24","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8827670","article-title":"Cellular and molecular immunology approaches for the development of immunotherapies against the new Coronavirus (SARS-CoV-2): challenges to near-future breakthroughs","volume":"2020","author":"Melga\u00e7o","year":"2020","journal-title":"J Immunol Res"},{"issue":"5","key":"10.1016\/bs.pmbts.2025.01.005_bib25","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/s12276-021-00592-0","article-title":"Type I and III interferon responses in SARS-CoV-2 infection","volume":"53","author":"Kim","year":"2021","journal-title":"Exp Mol Med"},{"issue":"1","key":"10.1016\/bs.pmbts.2025.01.005_bib26","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/jmv.27317","article-title":"The role of type I interferon in the treatment of COVID-19","volume":"94","author":"Sodeifian","year":"2022","journal-title":"J Med Virol"},{"issue":"5","key":"10.1016\/bs.pmbts.2025.01.005_bib27","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3349\/ymj.2021.62.5.381","article-title":"Roles of type I and III interferons in COVID-19","volume":"62","author":"Choi","year":"2021","journal-title":"Yonsei Med J"},{"issue":"4","key":"10.1016\/bs.pmbts.2025.01.005_bib28","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41423-020-00530-6","article-title":"Human immunology and immunotherapy: main achievements and challenges","volume":"18","author":"Varad\u00e9","year":"2021","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"10.1016\/bs.pmbts.2025.01.005_bib29","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41423-020-00530-6","article-title":"Human immunology and immunotherapy: main achievements and challenges","volume":"18","author":"Varad\u00e9","year":"2021","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"10.1016\/bs.pmbts.2025.01.005_bib30","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/cbin.11565","article-title":"Host-virus interaction and viral evasion","volume":"45","author":"Strumillo","year":"2021","journal-title":"Cell Biol Int"},{"issue":"5","key":"10.1016\/bs.pmbts.2025.01.005_bib31","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s12276-021-00602-1","article-title":"Innate immune sensing of coronavirus and viral evasion strategies","volume":"53","author":"Kasuga","year":"2021","journal-title":"Exp Mol Med"},{"issue":"6515","key":"10.1016\/bs.pmbts.2025.01.005_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"issue":"6","key":"10.1016\/bs.pmbts.2025.01.005_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202250164","article-title":"Autoantibodies targeting type I interferons: prevalence, mechanisms of induction, and association with viral disease susceptibility","volume":"53","author":"Hale","year":"2023","journal-title":"Eur J Immunol"},{"issue":"7988","key":"10.1016\/bs.pmbts.2025.01.005_bib34","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41586-023-06717-x","article-title":"Autoantibodies against type I IFNs in humans with alternative NF-\u03baB pathway deficiency","volume":"623","author":"Le Voyer","year":"2023","journal-title":"Nature"},{"issue":"8","key":"10.1016\/bs.pmbts.2025.01.005_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1327","article-title":"Antibodies against type I interferon: detection and association with severe clinical outcome in COVID-19 patients","volume":"10","author":"Goncalves","year":"2021","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/bs.pmbts.2025.01.005_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.606456","article-title":"Type I interferon (IFN)-regulated activation of canonical and non-canonical signaling pathways","volume":"11","author":"Mazewski","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/bs.pmbts.2025.01.005_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.953726","article-title":"Autoantibodies \u2013 enemies, and\/or potential allies?","volume":"13","author":"Ma","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/bs.pmbts.2025.01.005_bib38","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3892\/etm.2021.10444","article-title":"Overview of the pathogenesis of COVID-19 (review)","volume":"22","author":"Li","year":"2021","journal-title":"Exp Ther Med"},{"issue":"6","key":"10.1016\/bs.pmbts.2025.01.005_bib39","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s43440-021-00303-6","article-title":"Understanding the role of ACE-2 receptor in pathogenesis of COVID-19 disease: a potential approach for therapeutic intervention","volume":"73","author":"Shirbhate","year":"2021","journal-title":"Pharmacol Rep"},{"issue":"10","key":"10.1016\/bs.pmbts.2025.01.005_bib40","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41577-022-00762-9","article-title":"Understanding COVID-19-associated coagulopathy","volume":"22","author":"Conway","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"1 Pt 1","key":"10.1016\/bs.pmbts.2025.01.005_bib41","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.gene.2015.09.058","article-title":"The type I interferons: basic concepts and clinical relevance in immune-mediated inflammatory diseases","volume":"576","author":"L\u00f3pez de Padilla","year":"2016","journal-title":"Gene"},{"key":"10.1016\/bs.pmbts.2025.01.005_bib42","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2147\/JIR.S267280","article-title":"Role of IFN and complements system: innate immunity in SARS-CoV-2","volume":"13","author":"Shibabaw","year":"2020","journal-title":"J Inflamm Res"},{"issue":"14","key":"10.1016\/bs.pmbts.2025.01.005_bib43","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2022112907","article-title":"Viral recognition and the antiviral interferon response","volume":"42","author":"Dalskov","year":"2023","journal-title":"EMBO J"},{"issue":"4","key":"10.1016\/bs.pmbts.2025.01.005_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0000231","article-title":"Interferon-based agents for current and future viral respiratory infections: a scoping literature review of human studies","volume":"2","author":"Mesic","year":"2022","journal-title":"PLOS Glob Public Health"},{"issue":"9","key":"10.1016\/bs.pmbts.2025.01.005_bib45","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/nri888","article-title":"Viruses and interferon: a fight for supremacy","volume":"2","author":"Katze","year":"2002","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/bs.pmbts.2025.01.005_bib46","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/CMR.14.4.778-809.2001","article-title":"Antiviral actions of interferons","volume":"14","author":"Samuel","year":"2001","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"10.1016\/bs.pmbts.2025.01.005_bib47","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.4049\/jimmunol.1402794","article-title":"Interfering with immunity: detrimental role of type I IFNs during infection","volume":"194","author":"Stifter","year":"2015","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/bs.pmbts.2025.01.005_bib48","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.tim.2013.10.003","article-title":"Decoding the complexity of type I interferon to treat persistent viral infections","volume":"21","author":"Wilson","year":"2013","journal-title":"Trends Microbiol"},{"issue":"8","key":"10.1016\/bs.pmbts.2025.01.005_bib49","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1089\/1079990041689665","article-title":"Induction and regulation of IFNs during viral infections","volume":"24","author":"Malmgaard","year":"2004","journal-title":"J Interferon Cytokine Res"},{"issue":"6","key":"10.1016\/bs.pmbts.2025.01.005_bib50","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s41564-019-0421-x","article-title":"Decoding type I and III interferon signalling during viral infection","volume":"4","author":"Mesev","year":"2019","journal-title":"Nat Microbiol"},{"issue":"1","key":"10.1016\/bs.pmbts.2025.01.005_bib51","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2019-000336","article-title":"Type I interferons in host defence and inflammatory diseases","volume":"6","author":"Crow","year":"2019","journal-title":"Lupus Sci Med"},{"issue":"6","key":"10.1016\/bs.pmbts.2025.01.005_bib52","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1159\/000508379","article-title":"The role of type I IFNs in influenza: antiviral superheroes or immunopathogenic villains?","volume":"12","author":"Wu","year":"2020","journal-title":"J Innate Immun"},{"key":"10.1016\/bs.pmbts.2025.01.005_bib53","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cytogfr.2021.01.003","article-title":"Type I and III IFN-mediated antiviral actions counteracted by SARS-CoV-2 proteins and host inherited factors","volume":"58","author":"Quarleri","year":"2021","journal-title":"Cytokine Growth Factor Rev"},{"issue":"1","key":"10.1016\/bs.pmbts.2025.01.005_bib54","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41392-021-00733-x","article-title":"Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies","volume":"6","author":"Zhou","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/bs.pmbts.2025.01.005_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.05.001","article-title":"Type I interferon signaling, regulation and gene stimulation in chronic virus infection","volume":"43","author":"Lukhele","year":"2019","journal-title":"Semin Immunol"},{"issue":"1","key":"10.1016\/bs.pmbts.2025.01.005_bib56","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/bs.pmbts.2025.01.005_bib57","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3389\/fimmu.2017.01758","article-title":"Interplay between janus kinase\/signal transducer and activator of transcription signaling activated by type I interferons and viral antagonism","volume":"8","author":"Nan","year":"2017","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/bs.pmbts.2025.01.005_bib58","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1158\/1078-0432.CCR-10-1114","article-title":"Direct effects of type I interferons on cells of the immune system","volume":"17","author":"Hervas-Stubbs","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/bs.pmbts.2025.01.005_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2017.03.008","article-title":"Regulation of type I interferon signaling in immunity and inflammation: a comprehensive review","volume":"83","author":"Chen","year":"2017","journal-title":"J Autoimmunity"},{"issue":"11","key":"10.1016\/bs.pmbts.2025.01.005_bib60","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1038\/s12276-021-00691-y","article-title":"Regulation of antiviral innate immune signaling and viral evasion following viral genome sensing","volume":"53","author":"Chathuranga","year":"2021","journal-title":"Exp Mol Med"},{"issue":"3","key":"10.1016\/bs.pmbts.2025.01.005_bib61","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/ni.2229","article-title":"Intrinsic antiviral immunity","volume":"13","author":"Yan","year":"2012","journal-title":"Nat Immunol"},{"issue":"14","key":"10.1016\/bs.pmbts.2025.01.005_bib62","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2022112907","article-title":"Viral recognition and the antiviral interferon response","volume":"42","author":"Dalskov","year":"2023","journal-title":"Embo J"},{"key":"10.1016\/bs.pmbts.2025.01.005_bib63","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3389\/fimmu.2017.00259","article-title":"Type I Interferons As Regulators Of Lung Inflammation","volume":"8","author":"Makris","year":"2017","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/bs.pmbts.2025.01.005_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms11092179","article-title":"Interferons\u2014implications in the immune response to respiratory viruses","volume":"11","author":"Bergeron","year":"2023","journal-title":"Microorganisms"},{"issue":"5","key":"10.1016\/bs.pmbts.2025.01.005_bib65","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/icb.2012.9","article-title":"The interferons and their receptors\u2014distribution and regulation","volume":"90","author":"de Weerd","year":"2012","journal-title":"Immunol Cell Biol"},{"issue":"5","key":"10.1016\/bs.pmbts.2025.01.005_bib66","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1016\/bs.pmbts.2025.01.005_bib67","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41435-020-00116-2","article-title":"Host genetic susceptibility to viral infections: the role of type I interferon induction","volume":"21","author":"Bourdon","year":"2020","journal-title":"Genes Immun"},{"key":"10.1016\/bs.pmbts.2025.01.005_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.738073","article-title":"Immune response in severe and non-severe Coronavirus disease 2019 (COVID-19) infection: a mechanistic landscape","volume":"12","author":"Mukund","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/bs.pmbts.2025.01.005_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.888897","article-title":"Dysregulated interferon response and immune hyperactivation in severe COVID-19: targeting STATs as a novel therapeutic strategy","volume":"13","author":"Eskandarian Boroujeni","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/bs.pmbts.2025.01.005_bib70","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","article-title":"Therapeutic strategies for COVID-19: progress and lessons learned","volume":"22","author":"Li","year":"2023","journal-title":"Nat Rev Drug Discovery"},{"issue":"49","key":"10.1016\/bs.pmbts.2025.01.005_bib71","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abd1554","article-title":"Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19","volume":"5","author":"Lee","year":"2020","journal-title":"Sci Immunol"},{"issue":"49","key":"10.1016\/bs.pmbts.2025.01.005_bib72","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abd1554","article-title":"Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19","volume":"5","author":"Lee","year":"2020","journal-title":"Sci Immunol"},{"issue":"6504","key":"10.1016\/bs.pmbts.2025.01.005_bib73","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1126\/science.abc2061","article-title":"Type I and III interferons disrupt lung epithelial repair during recovery from viral infection","volume":"369","author":"Major","year":"2020","journal-title":"Science"},{"issue":"22","key":"10.1016\/bs.pmbts.2025.01.005_bib74","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.152288","article-title":"Human nasal wash RNA-Seq reveals distinct cell-specific innate immune responses in influenza versus SARS-CoV-2","volume":"6","author":"Gao","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/bs.pmbts.2025.01.005_bib75","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.coviro.2021.11.002","article-title":"Host cell-intrinsic innate immune recognition of SARS-CoV-2","volume":"52","author":"Madden","year":"2022","journal-title":"Curr Virol"},{"issue":"2","key":"10.1016\/bs.pmbts.2025.01.005_bib76","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41590-021-01091-0","article-title":"Innate immunity: the first line of defense against SARS-CoV-2","volume":"23","author":"Diamond","year":"2022","journal-title":"Nat Immunol"},{"issue":"6","key":"10.1016\/bs.pmbts.2025.01.005_bib77","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/s41418-022-01015-x","article-title":"Immune response in COVID-19: what is next?","volume":"29","author":"Li","year":"2022","journal-title":"Cell Death Differ"},{"key":"10.1016\/bs.pmbts.2025.01.005_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.vh.2021.06.011","article-title":"The interplay between the immune system and viruses","volume":"117","author":"Wubben","year":"2021","journal-title":"Vitam Horm"},{"key":"10.1016\/bs.pmbts.2025.01.005_bib79","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/B978-0-323-04404-2.10027-2","article-title":"Immune responses to viruses","author":"Mueller","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/bs.pmbts.2025.01.005_bib80","article-title":"Virus caused imbalance of type I IFN responses and inflammation in COVID-19","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/bs.pmbts.2025.01.005_bib81","first-page":"178","article-title":"Innate immune evasion strategies of SARS-CoV-2","volume":"21","author":"Minkoff","year":"2023","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"10.1016\/bs.pmbts.2025.01.005_bib82","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/IM9.0000000000000045","article-title":"The impact of SARS-CoV-2 on the human immune system and microbiome","volume":"3","author":"Wang","year":"2020","journal-title":"Infect Microbes Dis"},{"key":"10.1016\/bs.pmbts.2025.01.005_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2022.110495","article-title":"COVID-19 signalome: pathways for SARS-CoV-2 infection and impact on COVID-19 associated comorbidity","volume":"101","author":"Lundstrom","year":"2023","journal-title":"Cell Signal"},{"issue":"1","key":"10.1016\/bs.pmbts.2025.01.005_bib84","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/s41598-024-51505-w","article-title":"Measurement of IFN-\u03b3 and IL-2 for the assessment of the cellular immunity against SARS-CoV-2","volume":"14","author":"Safont","year":"2024","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/bs.pmbts.2025.01.005_bib85","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.jaip.2021.01.012","article-title":"Why do some people develop serious COVID-19 disease after infection, while others only exhibit mild symptoms?","volume":"9","author":"Ballow","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/bs.pmbts.2025.01.005_bib86","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-18244-2","article-title":"A simple model of COVID-19 explains disease severity and the effect of treatments","volume":"12","author":"Sanche","year":"2022","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/bs.pmbts.2025.01.005_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0281-8","article-title":"Interplay between host and pathogen: immune defense and beyond","volume":"51","author":"Jo","year":"2019","journal-title":"Exp Mol Med"},{"issue":"8","key":"10.1016\/bs.pmbts.2025.01.005_bib88","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22084190","article-title":"Type I interferon production of plasmacytoid dendritic cells under control","volume":"22","author":"Bencze","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/bs.pmbts.2025.01.005_bib89","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nri3806","article-title":"Regulation of antiviral T cell responses by type I interferons","volume":"15","author":"Crouse","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"10.1016\/bs.pmbts.2025.01.005_bib90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009708","article-title":"Antibody-independent functions of B cells during viral infections","volume":"17","author":"Upasani","year":"2021","journal-title":"PLOS Pathog"},{"issue":"2","key":"10.1016\/bs.pmbts.2025.01.005_bib91","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1084\/jem.20150712","article-title":"Type I IFN promotes NK cell expansion during viral infection by protecting NK cells against fratricide","volume":"213","author":"Madera","year":"2016","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/bs.pmbts.2025.01.005_bib92","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41577-021-00558-3","article-title":"Natural killer cells in antiviral immunity","volume":"22","author":"Bj\u00f6rkstr\u00f6m","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/bs.pmbts.2025.01.005_bib93","doi-asserted-by":"crossref","first-page":"7254","DOI":"10.1038\/s41467-022-34895-1","article-title":"Defective activation and regulation of type I interferon immunity is associated with increasing COVID-19 severity","volume":"13","author":"Smith","year":"2022","journal-title":"Nat Commun"},{"issue":"18","key":"10.1016\/bs.pmbts.2025.01.005_bib94","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810968","article-title":"Correlation between type I interferon associated factors and COVID-19 severity","volume":"23","author":"Bencze","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/bs.pmbts.2025.01.005_bib95","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12964-022-00903-6","article-title":"A comprehensive evaluation of the immune system response and type-I Interferon signaling pathway in hospitalized COVID-19 patients","volume":"20","author":"Soltani-Zangbar","year":"2022","journal-title":"Cell Commun Signal"},{"issue":"6504","key":"10.1016\/bs.pmbts.2025.01.005_bib96","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1126\/science.abc6027","article-title":"Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients","volume":"369","author":"Hadjadj","year":"2020","journal-title":"Science"},{"issue":"5","key":"10.1016\/bs.pmbts.2025.01.005_bib97","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/s12276-021-00592-0","article-title":"Type I and III interferon responses in SARS-CoV-2 infection","volume":"53","author":"Kim","year":"2021","journal-title":"Exp Mol Med"},{"issue":"12","key":"10.1016\/bs.pmbts.2025.01.005_bib98","doi-asserted-by":"crossref","DOI":"10.3390\/v12121433","article-title":"Dysregulated interferon response underlying severe COVID-19","volume":"12","author":"Lopez","year":"2020","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/bs.pmbts.2025.01.005_bib99","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41576-020-00297-6","article-title":"Host genetics and infectious disease: new tools, insights and translational opportunities","volume":"22","author":"Kwok","year":"2021","journal-title":"Nat Rev Genet"},{"key":"10.1016\/bs.pmbts.2025.01.005_bib100","series-title":"Human Genetic Variants Identified That Affect COVID Susceptibility and Severity","author":"Asgari","year":"2021"},{"issue":"9","key":"10.1016\/bs.pmbts.2025.01.005_bib101","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41576-022-00478-5","article-title":"The human genetic epidemiology of COVID-19","volume":"23","author":"Niemi","year":"2022","journal-title":"Nat Rev Genet"},{"issue":"1","key":"10.1016\/bs.pmbts.2025.01.005_bib102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41435-022-00192-6","article-title":"Gene\u2013environment interactions and their impact on human health","volume":"24","author":"Virolainen","year":"2023","journal-title":"Genes Immun"},{"issue":"3","key":"10.1016\/bs.pmbts.2025.01.005_bib103","article-title":"Transcriptional regulation by STAT1 and STAT2 in the interferon JAK-STAT pathway","volume":"2","author":"Au-Yeung","year":"2013","journal-title":"Jakstat"},{"issue":"2","key":"10.1016\/bs.pmbts.2025.01.005_bib104","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00251-022-01281-6","article-title":"Age-dependent effect of the IFIH1\/MDA5 gene variants on the risk of critical COVID-19","volume":"75","author":"Mu\u00f1iz-Banciella","year":"2023","journal-title":"Immunogenetics"},{"issue":"13","key":"10.1016\/bs.pmbts.2025.01.005_bib105","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.2174\/1389201023666220114162347","article-title":"An updated review on the role of single nucleotide polymorphisms in COVID-19 disease severity: a global aspect","volume":"23","author":"Ng","year":"2022","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/bs.pmbts.2025.01.005_bib106","doi-asserted-by":"crossref","DOI":"10.1038\/d41586-020-03070-1","article-title":"Interferon deficiency can lead to severe COVID","author":"Meffre","year":"2020","journal-title":"Nat Publ Group UK Lond"},{"key":"10.1016\/bs.pmbts.2025.01.005_bib107","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.cytogfr.2021.03.006","article-title":"COVID-19 as a mediator of interferon deficiency and hyperinflammation: rationale for the use of JAK1\/2 inhibitors in combination with interferon","volume":"60","author":"Hasselbalch","year":"2021","journal-title":"Cytokine Growth Factor Rev"},{"issue":"7","key":"10.1016\/bs.pmbts.2025.01.005_bib108","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/eji.202249824","article-title":"Anti-IFN-\u03b1\/-\u03c9 neutralizing antibodies from COVID-19 patients correlate with downregulation of IFN response and laboratory biomarkers of disease severity","volume":"52","author":"Frasca","year":"2022","journal-title":"Eur J Immunol"},{"key":"10.1016\/bs.pmbts.2025.01.005_bib109","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3389\/fimmu.2017.00873","article-title":"The role of interferons in inflammation and inflammasome activation","volume":"8","author":"Kopitar-Jerala","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/bs.pmbts.2025.01.005_bib110","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.3389\/fimmu.2018.02061","article-title":"The dual nature of type I and type II interferons","volume":"9","author":"Lee","year":"2018","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/bs.pmbts.2025.01.005_bib111","first-page":"231","article-title":"COVID-19 pathogenesis and clinical manifestations","volume":"36","author":"Acosta","year":"2022","journal-title":"Infect Dis Clin"},{"key":"10.1016\/bs.pmbts.2025.01.005_bib112","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.723532","article-title":"Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy","volume":"9","author":"Ferr\u00e9","year":"2021","journal-title":"Front Pediatr"},{"key":"10.1016\/bs.pmbts.2025.01.005_bib113","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.788368","article-title":"Anti-interferon autoantibodies in adult-onset immunodeficiency syndrome and severe COVID-19 infection","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"issue":"20","key":"10.1016\/bs.pmbts.2025.01.005_bib114","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10204729","article-title":"Autoimmunity in primary immunodeficiency disorders: an updated review on pathogenic and clinical implications","volume":"10","author":"Costagliola","year":"2021","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/bs.pmbts.2025.01.005_bib115","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens11030311","article-title":"Molecular and clinical prognostic biomarkers of COVID-19 severity and persistence","volume":"11","author":"Papadopoulou","year":"2022","journal-title":"Pathogens"},{"issue":"2","key":"10.1016\/bs.pmbts.2025.01.005_bib116","article-title":"COVID-19 impact on diagnostic innovations: emerging trends and implications","volume":"11","author":"Oyewole","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"3","key":"10.1016\/bs.pmbts.2025.01.005_bib117","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41579-020-00461-z","article-title":"Considerations for diagnostic COVID-19 tests","volume":"19","author":"Vandenberg","year":"2021","journal-title":"Nat Rev Microbiol"},{"issue":"9","key":"10.1016\/bs.pmbts.2025.01.005_bib118","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1007\/s00216-022-03918-7","article-title":"Diagnostic assay and technology advancement for detecting SARS-CoV-2 infections causing the COVID-19 pandemic","volume":"414","author":"Dhar","year":"2022","journal-title":"Anal Bioanal Chem"},{"issue":"8","key":"10.1016\/bs.pmbts.2025.01.005_bib119","article-title":"Detection of neutralizing anti-type 1 interferon autoantibodies","volume":"2","author":"Shaw","year":"2022","journal-title":"Curr Protoc"},{"issue":"1","key":"10.1016\/bs.pmbts.2025.01.005_bib120","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41525-021-00196-7","article-title":"STAT1 gain-of-function heterozygous cell models reveal diverse interferon-signature gene transcriptional responses","volume":"6","author":"Scott","year":"2021","journal-title":"npj Genomic Med"},{"issue":"5","key":"10.1016\/bs.pmbts.2025.01.005_bib121","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1159\/000495897","article-title":"Type I interferons: distinct biological activities and current applications for viral infection","volume":"51","author":"Li","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/bs.pmbts.2025.01.005_bib122","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.3389\/fimmu.2018.02367","article-title":"Immune functional assays, from custom to standardized tests for precision medicine","volume":"9","author":"Albert-Vega","year":"2018","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/bs.pmbts.2025.01.005_bib123","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0258064","article-title":"How the scientific community responded to the COVID-19 pandemic: a subject-level time-trend bibliometric analysis","volume":"16","author":"Malekpour","year":"2021","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/bs.pmbts.2025.01.005_bib124","article-title":"Integration of multiple interferometers in highly multiplexed diagnostic KITs to evaluate several biomarkers of COVID-19 in serum","volume":"12","author":"Murillo","year":"2022","journal-title":"Biosens (Basel)"},{"key":"10.1016\/bs.pmbts.2025.01.005_bib125","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/B978-0-323-85156-5.00034-1","article-title":"Biomarkers, tools, and test kits for COVID-19","author":"Kumar Jena","year":"2022","journal-title":"Coronavirus Drug Discovery"},{"key":"10.1016\/bs.pmbts.2025.01.005_bib126","series-title":"Translational biotechnology","first-page":"137","article-title":"Chapter 6 \u2013 Biological therapeutic modalities","author":"Chhabra","year":"2021"},{"issue":"4","key":"10.1016\/bs.pmbts.2025.01.005_bib127","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4155\/tde-2020-0035","article-title":"COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics","volume":"11","author":"Amawi","year":"2020","journal-title":"Therapeutic Deliv"},{"key":"10.1016\/bs.pmbts.2025.01.005_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113649","article-title":"Advances in nanomaterial-based immunosensors for prostate cancer screening","volume":"155","author":"Khan","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/bs.pmbts.2025.01.005_bib129","series-title":"COVID-19: From Bench to Bedside","first-page":"1","article-title":"Therapeutic challenges in COVID","author":"Aljabali","year":"2022"},{"key":"10.1016\/bs.pmbts.2025.01.005_bib130","doi-asserted-by":"crossref","DOI":"10.3949\/ccjm.87a.ccc066","article-title":"Interferon therapy for COVID-19 and emerging infections: prospects and concerns","author":"Calabrese","year":"2020","journal-title":"Cleve Clin J Med"},{"issue":"20","key":"10.1016\/bs.pmbts.2025.01.005_bib131","doi-asserted-by":"crossref","first-page":"11799","DOI":"10.1093\/nar\/gkaa961","article-title":"Synthetic rewiring and boosting type I interferon responses for visualization and counteracting viral infections","volume":"48","author":"G\u00f6decke","year":"2020","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"10.1016\/bs.pmbts.2025.01.005_bib132","doi-asserted-by":"crossref","DOI":"10.3390\/v14051107","article-title":"Type I and type II interferon antagonism strategies used by paramyxoviridae: previous and new discoveries, in comparison","volume":"14","author":"Pisanelli","year":"2022","journal-title":"Viruses"},{"issue":"8","key":"10.1016\/bs.pmbts.2025.01.005_bib133","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms11082101","article-title":"Type I interferon pathway-related hub genes as a potential therapeutic target for SARS-CoV-2 omicron variant-induced symptoms","volume":"11","author":"Lin","year":"2023","journal-title":"Microorganisms"},{"issue":"4","key":"10.1016\/bs.pmbts.2025.01.005_bib134","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/ped4.12226","article-title":"Type I interferon: from innate response to treatment for COVID-19","volume":"4","author":"Lin","year":"2020","journal-title":"Pediatr Investig"},{"issue":"4","key":"10.1016\/bs.pmbts.2025.01.005_bib135","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cytogfr.2014.07.015","article-title":"Interferons: success in anti-viral immunotherapy","volume":"25","author":"Lin","year":"2014","journal-title":"Cytokine Growth Factor Rev"}],"container-title":["Progress in Molecular Biology and Translational Science","Navigating the Complexities of SARS-CoV-2 Immunobiology: The Science Behind the COVID-19 Pandemic"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117325000171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117325000171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T15:34:42Z","timestamp":1744731282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877117325000171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443238321"],"references-count":135,"URL":"https:\/\/doi.org\/10.1016\/bs.pmbts.2025.01.005","relation":{},"ISSN":["1877-1173"],"issn-type":[{"value":"1877-1173","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}